RBC Capital analyst Adnan Butt recently named 12 biotech stocks with major binary events expected in 2016.
Here’s a breakdown of the full list.
- Aerie Pharmaceuticals Inc AERI 7.59%: Phase 3 data for Rhopressa and Roclatan
- Aptose Biosciences Inc APTO 1.72%: Phase 1 data for APTO-253
- ArQule, Inc. ARQL 4.5%: Phase 3 interim for tivantinib and Phase 1 data/update for ARQ-092 in Proteus syndrome
- Curis, Inc. CRIS 4.52%: Phase 1 update from CUDC-907, CA-170 and potential additional programs
- Endocyte, Inc. NASDAQECTY: Phase 1 data for EC1456 and EC1169
- Intra-Cellular Therapies Inc ITCI 5.53%: Phase 3…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
